TY - JOUR
T1 - Treatment Factors Associated With Overall Survival in Retroperitoneal Sarcoma
T2 - An Institutional Review
AU - Kwong, Mei L.
AU - Lee, Becky
AU - Kunihira, Karissa
AU - Sutjiadi, Brian
AU - Reeves, Mark E.
AU - Selleck, Matthew
AU - Yang, Gary
AU - Solomon, Naveenraj
N1 - Publisher Copyright:
© The Author(s) 2020.
PY - 2020/10
Y1 - 2020/10
N2 - INTRODUCTION: Retroperitoneal sarcoma (RPS) is a rare malignancy, and curative resection is considered the main therapy. Use of chemotherapy and/or radiation in addition to surgery (multimodality therapy) is controversial.OBJECTIVE: To determine treatment factors that influence overall survival in RPS.METHODS: This retrospective Institutional Review Board-approved study identified patients with RPS treated at a single institution between 2000 and 2017. Patient, tumor, and treatment modalities were collected. Prism (v.8.2.1) was used to calculate Kaplan-Meier survival curves.RESULTS: There were 695 patients with sarcoma between 2000 and 2017, and 61 adults had RPS. The mean age was 59 (range 31-86) years, with 57.4% females (n = 35). Patients were 68.9% Caucasian (n = 42), 21.3% Hispanic (n = 13), 8.2% black (n = 5), and 1.6% Asian (n = 1). There were 4 patients who had neoadjuvant therapy (chemotherapy, n = 3; radiation, n = 2) and 17 who had adjuvant therapy (chemotherapy, n = 6; radiation, n = 14). There was no significant difference in survival between the groups who received multimodality therapy compared to surgery alone. There was a significant improvement in the median overall survival for patients who underwent one or multiple surgeries (
P < .05).
CONCLUSIONS: These institutional data suggest that treatment factors associated with overall survival included multiple resections. Use of multimodality therapy was low and did not influence overall survival in patients with RPS compared to surgery alone.
AB - INTRODUCTION: Retroperitoneal sarcoma (RPS) is a rare malignancy, and curative resection is considered the main therapy. Use of chemotherapy and/or radiation in addition to surgery (multimodality therapy) is controversial.OBJECTIVE: To determine treatment factors that influence overall survival in RPS.METHODS: This retrospective Institutional Review Board-approved study identified patients with RPS treated at a single institution between 2000 and 2017. Patient, tumor, and treatment modalities were collected. Prism (v.8.2.1) was used to calculate Kaplan-Meier survival curves.RESULTS: There were 695 patients with sarcoma between 2000 and 2017, and 61 adults had RPS. The mean age was 59 (range 31-86) years, with 57.4% females (n = 35). Patients were 68.9% Caucasian (n = 42), 21.3% Hispanic (n = 13), 8.2% black (n = 5), and 1.6% Asian (n = 1). There were 4 patients who had neoadjuvant therapy (chemotherapy, n = 3; radiation, n = 2) and 17 who had adjuvant therapy (chemotherapy, n = 6; radiation, n = 14). There was no significant difference in survival between the groups who received multimodality therapy compared to surgery alone. There was a significant improvement in the median overall survival for patients who underwent one or multiple surgeries (
P < .05).
CONCLUSIONS: These institutional data suggest that treatment factors associated with overall survival included multiple resections. Use of multimodality therapy was low and did not influence overall survival in patients with RPS compared to surgery alone.
KW - multimodality therapy
KW - retroperitoneal
KW - sarcoma
KW - Retroperitoneal Neoplasms/mortality
KW - Sarcoma/mortality
KW - Humans
KW - Middle Aged
KW - Male
KW - Combined Modality Therapy
KW - Survival Analysis
KW - Aged, 80 and over
KW - Adult
KW - Female
KW - Aged
KW - Retrospective Studies
UR - http://www.scopus.com/inward/record.url?scp=85097263304&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097263304&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/547b03f5-2b48-3eff-b1a0-90caa85aa5cd/
U2 - 10.1177/0003134820964460
DO - 10.1177/0003134820964460
M3 - Article
C2 - 33124890
SN - 0003-1348
VL - 86
SP - 1358
EP - 1362
JO - American Surgeon
JF - American Surgeon
IS - 10
ER -